OPENBIOME FOUNDATION INC
Programs
Fecal Microbiota Transplant Program
OPENBIOME REMAINED COMMITTED TO ENSURING THAT ALL PATIENTS SUFFERING FROM C. DIFFICILE INFECTION CONTINUED TO HAVE SAFE, CONVENIENT, AND AFFORDABLE ACCESS TO FECAL MICROBIOTA TRANSPLANTATION (FMT) THROUGH THEIR PHYSICIAN. IN OUR COLLABORATION WITH THE UNIVERSITY OF MINNESOTA (UMN), UNDER AN ACTIVE INVESTIGATIONAL NEW DRUG (IND), WE CONTINUED TO DISTRIBUTE FMT TO OUR CLINICAL NETWORK. HOWEVER, IN MID-YEAR, REGULATORY CHANGES NECESSITATED THAT WE CEASE PROVIDING THESE TREATMENTS. AFTER 12 YEARS AND OVER 72,000 TREATMENTS, WE HAD NO CHOICE BUT TO DISCONTINUE THIS PROGRAM.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$2.4MClinical Research Program
CLINICAL RESEARCH PROGRAM: OPENBIOME SEEKS TO ENABLE TRANSLATIONAL RESEARCH ON THE HUMAN MICROBIOME. TO ACHIEVE THIS, WE OFFER A SUITE OF SERVICES DESIGNED TO HELP INVESTIGATORS UNCOVER THE ROLE OF THE GUT MICROBIOME IN HUMAN HEALTH AND EXPLORE HOW ENGINEERING IT CAN LEAD TO IMPROVED HEALTH OUTCOMES. OUR SERVICES INCLUDE STUDY DESIGN AND REGULATORY SUPPORT FOR CLINICAL TRIALS, AND BIOINFORMATICS AND ANALYTICAL SERVICES. OPENBIOME ALSO SPONSORS ITS OWN STUDIES INVESTIGATING CRITICAL MICROBIOME-RELATED HEALTH CONDITIONS.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$49.4KGlobal Microbiome Conservancy
THE GLOBAL MICROBIOME CONSERVANCY (GMBC) PARTNERS WITH SCIENTISTS WORLDWIDE TO CONSERVE, STUDY, AND SHARE THE UNDERREPRESENTED AND AT-RISK DIVERSITY OF HUMAN MICROBIOMES. THE GMBC HAS ESTABLISHED A NETWORK OF 80+ RESEARCHERS IN OVER THREE DOZEN COUNTRIES AND BUILT A DIVERSE COLLECTION OF SAMPLES AND BACTERIAL ISOLATES TO SPARK SCIENTIFIC DISCOVERY AND ENABLE NEW SOLUTIONS TO MICROBIOME-ASSOCIATED DISEASE. IN 2024, OPENBIOME SUPPORTED THIS PROGRAM BY PROVIDING GRANTS TO AID IN THE COLLECTION OF SAMPLES AND ISOLATES IN VARIOUS COUNTRIES.GeographiesNot indicatedDatesJan 1, 2024 – Dec 31, 2024Source990No causes providedNo populations provided–$300K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)